Prime Medicine, a company founded with gene editing technology from Harvard biochemist David Liu, initially planned to use its technology across 18 different diseases but has since scaled back its aims to focus on just three genetic diseases due to financial constraints. The company announced a new cell therapy pact with Bristol Myers Squibb, bringing in $110 million immediately and potentially more in milestones. Prime’s decision to narrow its pipeline aligns with other biotechs facing similar challenges. Although it has shelved ambitious projects, it aims to establish its technology in key areas like chronic granulomatous disease, Wilson’s disease, and cystic fibrosis.
Source link
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
